To study the role of probiotics on gut permeability and endotoxemia in patients with acute pancreatitis (AP).
A cute pancreatitis (AP) is a common abdominal emergency with pancreatic necrosis complicating severe attacks. Necrosis may become infected, thereby increasing mortality to more than 40%. [1] [2] [3] [4] Small bowel bacterial overgrowth and subsequent bacterial translocation (BT) may be responsible for the majority of these infections. [5] [6] [7] [8] [9] The breakdown of intestinal mucosal integrity alters intestinal permeability and may be implicated in BT. The maintenance of gut barrier integrity is one of the goals in the treatment of AP. Liu et al 10 found that intestinal mucosal function is impaired in the early phase of AP, especially in patients with organ dysfunction, which correlates with bad outcome.
Various modalities have been used to alter the gut flora, and studies on the effect of outcome of AP yielded varying results. [11] [12] [13] [14] It has been shown that early antibiotic treatment is associated with a significant improvement in the prognosis of necrotizing AP, because of reduction in the occurrence of complications. 15 Intravenous antibiotic prophylaxis is considered an option to prevent pancreatic infection, but results from randomized clinical trials are conflicting. [11] [12] [13] [14] [15] [16] A meta-analysis of 6 studies showed that prophylactic antibiotics did not prevent infected necrosis or death in acute necrotizing pancreatitis, 16, 17 except in the group that received imipenem as the prophylactic antibiotic in which mortality decreased significantly. 18 Another disadvantage observed with prophylactic antibiotics is risks of bacterial resistance and fungal infection. 19, 20 Several trials with enteral probiotics have shown a significant reduction of infectious complications both in AP and in patients undergoing major abdominal surgery. [21] [22] [23] [24] A well-designed placebo-controlled trial with Lactobacillus plantarum in patients with AP has shown a significant reduction of infected pancreatic necrosis (1 of 22 vs. 7 of 23 infected necrosis). 22 However, this study received criticism because of the exclusion of patients with biliary pancreatitis and statistical flaws. 25, 26 A recently conducted trial on prevention of infectious complications by probiotics found that a significantly lower percentage (38.9%) of patients with enteral feeding in the probiotic group were colonized with multiple organisms compared with 73.7% in the parenteral nutrition group (P<0.01), and only 30.6% patients in the enteral group grew potentially pathogenic organisms compared with 50% patients in parenteral nutrition group (P<0.05). 27 This study pointed out the use of probiotics as a modifier of bacterial flora to be of potentially beneficial effect in preventing infectious complications. The literature neither conclusively favors nor is against the use of probiotics to prevent infectious complications; hence, we planned this randomized controlled trial with the objective to study the role of probiotics on gut permeability and endotoxemia (indirect markers of increased infectious complications) in patients with AP.
MATERIALS AND METHODS

Study Design
A double-blind, randomized placebo-controlled trial.
Patients
All consecutive patients with AP admitted to the ward of Department of Gastroenterology in our hospital were evaluated for inclusion in the study. The study had to be abandoned after the publication of probiotic prophylaxis in patients with predicted severe acute pancreatitis (PRO-PATRIA) trial, 28 which showed excessive mortality and infection with probiotics. The period of study was from March 2007 to May 2008.
Inclusion Criteria
Patients with AP presenting within the first 72 hours after the onset of abdominal pain or had been nil orally at the time of presentation for up to 5 days.
Exclusion Criteria
Patients with the following conditions were excluded: (a) Malignancy, (b) Infection or sepsis related to source other than pancreatic bed, (c) Intraoperative diagnosis of AP, (d) Immunodeficiency, (e) Earlier use of probiotics or prebiotics, and (f) Pregnant ladies.
Diagnosis of AP
The diagnosis of AP was established on the basis of acute onset of typical pain with at least 3-fold increase in levels of serum amylase and ultrasonographic evidence of pancreatitis. Computerized tomographic (CT) scan was used as a diagnostic modality only when equivocal findings were present.
Clinical Work-up of Patients
After the diagnosis of pancreatitis, meticulous clinical records, baseline and serial Acute Physiology and Chronic Health Evaluation II scores, and blood tests including complete blood count, electrolytes, blood sugar, renal and liver function tests, serum amylase, and arterial blood gas analysis were carried out on admission and subsequently as per requirement. The severity of AP was assessed clinically as per the Atlanta classification into mild and severe groups. Contrast enhanced CT scan of the abdomen was taken for evaluation of necrotizing pancreatitis or after the development of complications. CT severity index as a morphological indicator of severity was calculated.
All patients received the standard medical treatment in the form of antibiotics, fluid, and electrolytes along with nutrition support, and other support for organ failure was given to the patients as and when required.
Study Intervention Randomization and Method of Allocation Concealment
The study patients were to receive either probiotics or placebo. Randomization was done by a random number sequence generated by a statistician not associated with the conduct of the study. The method of allocation concealment was sequentially numbered sealed opaque envelopes technique. Double blinding was done to ensure minimum bias. The clinician attending the patients were not involved in the randomization process and were blinded to the type of treatment received by the patients. The patients were blinded to the identity of the intervention that they were receiving because the placebo was identical to the probiotics in packaging, appearance, and schedule of administration.
Study Medication
Four sachets of Probiotics (about 2.5 billion bacteria per sachet containing Lactobacillus acidophilus, Bifidobacterium longus, Bifidobacterium bifidum, and Bifidobacterium infantalis with 25 mg of fructo-oligosaccharide) per day were given as per the current mode of feeding in patients (oral, nasojejunal, or nasogastric). The study medication and placebo was provided by Alkem. To assure maximum delivery and colonization of these probiotics, first, we assured a 4-hour to 6-hour gap between study medication and antibiotics (if prescribed) and second, we gave probiotics in high doses, which ensured the delivery of required doses.
Duration of Study
The duration of intervention was 7 days. The patients who were discharged within 7 days were provided with (study medication) sachets and were called for sampling and follow-up at 7 days.
Primary Outcome Measures
Effect on gut permeability and endotoxemia by prevention of BT and restoring the intestinal permeability.
Secondary Outcome Measures Clinical endpoint
Mortality, total hospital stay, duration of intensive care unit (ICU) stay, side effects, abdominal discomfort, and organ failure.
Biochemical
Serum levels of C-reactive protein (CRP) and prealbumin.
Methods of Biochemical Estimations
CRP: The hsCRP enzyme-linked immunosorbant assay (ELISA), based on the principal of solid phase ELISA, was used for the CRP assay (Biochek).
Human Prealbumin: Human prealbumin was measured with the principal of double antibody sandwich ELISA. (Immunology Consultants Laboratory, Inc. Newberg).
Estimation of Gut Permeability (Intestinal Permeability)
Gut permeability was assessed by urinary excretion of lactulose and mannitol. The results were expressed as the ratio of percentage excretion of the ingested dose of lactulose and mannitol in urine [lactulose/mannitol ratio (LMR)=% lactulose/% mannitol].
Test Procedure of LMR
After an overnight fast, the patients evacuated the urinary bladder, collected a pretest sample, and then drank the test solution containing 10 g of lactulose and 5 g of mannitol, in 50 mL of water. No food or drink other than water was allowed until the completion of the test. Water was allowed after 1 hour of ingestion of the test solution. All the urine that passed in the subsequent 5 hours was collected into a plastic can containing 2% chlorhexidine as a preservative. Aliquots of the collected urine were stored at À201C until analysis.
Estimation of Mannitol and Lactulose in Urine
Lactulose was estimated using the Selivanoff method 29 for quantitating ketose sugars, and mannitol was estimated using the method described by Corcoran and Page. 30 The lactulose and mannitol content was determined by using a standard calibration curve constructed using known concentrations of lactulose and mannitol. Lactulose is a prebiotic, which favors lactic acid-forming bacteria. Thus, its use in assessing gut permeability may confound the results.
Estimation of Endotoxemia
Markers of endotoxemia (IgG and IgM) were measured with Endocab ELISA kit (Hycult Biotechnology, Netherlands). The kit has a minimum detection level of 0.125 GMU of IgG Endocab (endotoxin core antibody) antibodies and 0.055 MMU/mL of IgM Endocab antibodies. The kit is based on solid-phase ELISA on the sandwich principle. This test is an antibody against Endotoxin; manufacturer instructions suggest that a drop in antibody levels means more endotoxemia.
All biochemical, gut permeability, and endotoxemia markers were estimated just before and 7 days after intervention.
Statistical Analysis
Descriptive statistics (mean, standard deviation/median, and range) for continuous covariates, and frequency, percentage, and proportions were used for categorical variables. For continuous variable, the 2 groups were compared using Mann-Whitney test wherever applicable, and for comparison of categorical variables the Wilcoxon signed rank test have been applied wherever applicable. P value <0.05 was considered to be statistically significant. All statistical analyses were contemplated with STATA 9.0 (Statacorp, TX). The intention-to-treat analysis was carried out to compare the 2 groups.
Sample Size Calculation
Considering the anticipated mean±SD of L/M at day 7 in the placebo group as 0.3±0.15 (based on pilot study data) and mean±SD of L/M in the probiotic group on day 7 as 0.2±0.15, to detect this difference with 95% level of confidence and 80% power, we required 36 patients in each group. However, considering loss to follow-up, we decided to enroll 45 patients in each group.
Ethical Considerations
The study was approved by the ethics committee of All India Institute of medical sciences New Delhi, India. The purpose of the study was explained clearly to the patients and their informed written consent was obtained. The trial is registered at Clinical Trial Registry-India (CTRI No-CTRI/2009/091/000933). CONSORT guidelines for conduction of a randomized study were followed (Fig. 1) .
RESULTS
Of 121 patients admitted to the Gastroenterology ward during the study period, 71 patients were excluded from the study, as they did not meet the inclusion criteria. The remaining 50 patients were randomized: 26 to the placebo and 24 to the probiotics arm. Clinical, Demographic, and Biochemical Parameters (Table 1) The mean age of the patients, sex distribution, duration of pain, and Acute Physiology and Chronic Health Evaluation II scores at admission were comparable in the 2 groups at baseline (Table 1 ). A total of 22 patients had severe acute pancreatitis (SAP), whereas 28 patients had mild AP.
All the 22 patients with SAP received antibiotics, 11 patients in each group. The baseline biochemical parameters were also comparable in both the groups ( Table 2 ). The etiology in the placebo group was gallstones in 11 (42.3%), alcohol in 3 (11.5%), post-endoscopic retrograde cholangiopancreatography in 4 (15.3%), and idiopathic in 8 (30.7%) patients. The etiology in the probiotic group was gallstone in 11 (45.83%), alcohol in 2 (8.33%), post-endoscopic retrograde cholangiopancreatography in 5 (20.8%), and idiopathic in 6 (25%) patients.
Response to Treatment Primary Outcome Measures
The values of LM ratio and IgG and IgM at day 1 and after intervention of 7 days are shown in Table 2 . There was no statistically significant difference between the groups after intervention in gut permeability as measured by LMR whereas immunoglobulins decreased significantly in the probiotic group (Table 2) .
Secondary Outcome Measures
(a) Biochemical There was no difference in prealbumin values in both the groups after supplementation. CRP values decreased in both the groups, but were statistically significant in the probiotic group (Table 2) .
(b) Clinical endpoint There was no difference in the duration of hospital stay [9.69±9.69, 6 (1 to 45) vs. 13.23±18.19, 5 (2 to 69) days, P=0.76] or in the duration of ICU stay [4±5.86, 1.5 (0 to 22) vs. 4.94±9.54, 1 (0 to 40) days, P=0.94] in the placebo and probiotic group, respectively. Four (2 in each group) patients died during hospitalization owing to persistent organ failure, and all had extensive pancreatic necrosis and sepsis.
Blood culture in the placebo group grew Klebsiella and coagulase-positive staphylococcus in 2 patients and budding yeast in the urine culture of 1 patient. In the probiotic group, blood culture grew Acinetobacter and candida, and urine culture showed pseudomonas and yeast in 2 patients each.
There were no side effects reported by patients in both the groups. 
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DISCUSSION
This double-blind, placebo-controlled trial was carried out in patients with AP with the aim to see the effect of probiotics on intestinal permeability and endotoxemia. We did not find any difference between the 2 groups as far as restoration of altered intestinal permeability (IP) was concerned. There was a fall in the markers of endotoxemia (IgG, IgM) and in CRP in the probiotic group, which did not translate into clinical improvement as evidenced by hospital stay or mortality. As the sample size of this study was small, the results obtained with probiotics cannot be advocated for routine administration in patients with AP irrespective of the severity of disease.
There were similar levels of serum albumin in the 2 groups at baseline and after 7 days. There was a decline in the serum prealbumin levels at the end of 7 days although not significant in both the groups. This probably occurred because AP is a hypermetabolic state with an increase in the expenditure of resting energy, and calorie intake in the study population was inadequate. Similar results have been reported in our earlier study. 31 Although the CRP values of both the groups were comparable at baseline, there was a significant fall after 7 days in the probiotic group. There is a trend toward decrease in the values of CRP in the placebo group although not significant. Impaired intestinal permeability has been reported in experimental models of AP. [32] [33] [34] [35] [36] In the natural course of disease, intestinal permeability has been found to increase with time but gets restored between day 8 and day 45. 37 It has been seen in various studies that compared with controls, IP in mild and severe AP is significantly high at onset. In addition, it has been shown that the increase in IP is gradual, and by day 15, the values start decreasing but do not normalize. [38] [39] [40] In this study we found that the baseline values of urinary L/M were comparable in the 2 groups and there was no significant change after probiotic therapy. The possible explanation for this is that both the groups of patients were fed enterally, which could have maintained the gut mucosal barrier and a small sample. In earlier studies in critically ill patients, it has been shown that intestinal permeability showed a progressive and significant fall when early enteral nutrition was administered. 37 Gram-negative bacteria of intestinal origin are the most frequently isolated microorganisms in infected necrosis, which likely supports the contention of associated gut barrier dysfunction. BT is defined as the passage of microorganisms of intestinal origin, or their products through an apparently intact intestinal wall reaching the mesenteric lymph nodes and other territories. Although the route of migration is not completely known, a dysfunction of the gut barrier, together with bacterial colonization of the mesenteric lymph nodes and other organs has been shown in animal models of AP. 40 Endotoxin is a key component of the wall of gram-negative bacteria, its main components being the O-antigenic polysaccharide and lipid A, and endotoxin translocation from the intestinal lumen to the systemic circulation has been associated with the development of the systemic inflammatory response syndrome, multiorgan failure, and mortality. 37 Endotoxin has been shown to be involved in the development of the systemic inflammatory response syndrome and septic shock. 38 Among the mediators associated with cardiovascular alterations occurring in septic shock, it has been observed that the increased production of tumor necrosis factor-a and nitric oxide play an important role. Experimental studies have shown that the intravenous administration of endotoxin is associated with hyperdynamic circulatory changes and the increase in the production of interleukin-2, interleukin-6, and prostaglandin E2. Endotoxemia has been shown to be directly related to the severity of episodes of AP, being more relevant in patients with SAP.
The IgM antibody titer is an indirect marker for endotoxin levels, and endotoxemia peaks coincidentally with lower levels of Endocab IgM antibody. We found a significant fall in IgM and IgG in the group receiving probiotics (suggesting increased endotoxemia) after 7 days of intervention, in contrast with an earlier study by Qin et al 27 who showed that there is decrease in the colonization of pathogenic bacteria in the gut if probiotics are used. Although in this study we did not culture the gut flora, but from results it is imperative that nonpathogenic bacterial colonization and some pathogenic bacteria grow, which may lead to endotoxemia. Animal studies have shown that gut flora pretreatment with synbiotics can effectively protect against endotoxin/BT, in the course of AP and concomitant heavy alcohol consumption. 40 Two small placebo-controlled randomized controlled trials of probiotic prophylaxis have been conducted in patients with AP. The first study randomized 45 patients with both predicted mild and predicted severe pancreatitis of solely nonbiliary causes. 22 The infection rate was lower in the probiotic group than in the placebo group; no effect on mortality was noted. However, this study was criticized because patients with biliary pancreatitis were excluded, the sample size was small, and analyses were not by intention to treat. 25, 26 In the second trial, conducted by the same research group in 62 patients with predicted severe pancreatitis, the difference in the rate of infectious complications seen in the first trial could not be reproduced. This second study used a probiotic preparation that was earlier found to be effective in preventing infectious complications in patients undergoing abdominal operations. 41 We did not find difference between the 2 groups in intestinal permeability, infectious complications, or overall survival, possibly reflecting the fact that despite IP, endotoxemia, and infectious complications being related, they are occurring at different points in the natural course of AP.
Results of this study were comparable with recently concluded multicentric double-blind placebo-controlled read trial, 41 but in stark contrast with earlier published reports. 28 We looked for methodology errors to explain these results. Randomization was successful as evidenced by comparable baseline characteristics of the 2 groups. The dose of probiotics was similar to that used in earlier studies but the composition was not the same. Individual probiotic strains have been used as probiotics in earlier clinical trials and have been shown to suppress the pathogenic gut flora and modulate immune response.
This was a prospective study: planning in advance the ensured collection of all required data; all patients admitted during the study period were included and followed for length of stay and outcome of the disease. However, possible limitation was that the study had to be abandoned after the publication of the PROPATRIA trial, therefore, there was insufficient enrollment to reach definitive conclusion on primary endpoints.
The PROPATRIA 28 trial on patients with predicted severe AP, probiotic prophylaxis with the same combination of probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of mortality. We also did not find significant difference in infectious complications between placebo and probiotics. With increased mortality in the probiotic arm, as reported in PROPATRIA trial, further studies should be undertaken with caution.
We conclude that in this study, no significant trend was identified for an effect of probiotics on gut permeability, endotoxemia, or clinical outcome viz. mortality, ICU stay, length of hospital stay, and infectious complications in AP. However, this study was underpowered owing to premature study termination.
